Is GMP required by FDA?
Yes. For drugs marketed in the United States, FDA requires compliance with applicable Current Good Manufacturing Practice (CGMP) requirements. For finished pharmaceuticals, key requirements are contained in 21 CFR Parts 210 and 211, although applicable regulations differ by product type.
Answer
Yes. Pharmaceutical manufacturers supplying drugs to the United States must comply with applicable FDA Current Good Manufacturing Practice requirements.
For finished pharmaceuticals, FDA’s core CGMP regulations include:
21 CFR Part 210 — Current Good Manufacturing Practice in manufacturing, processing, packing, or holding of drugs.
21 CFR Part 211 — Current Good Manufacturing Practice for finished pharmaceuticals.
These requirements address areas including:
– personnel
– buildings and facilities
– equipment
– components and containers
– production and process controls
– packaging and labeling
– laboratory controls
– records and reports
– returned and salvaged products
Failure to manufacture a drug in conformity with applicable CGMP requirements can cause the product to be considered adulterated under U.S. law, regardless of whether a specific quality defect has been identified in the finished medicine.
FDA assesses compliance through mechanisms including establishment inspections, record review, product testing, and other regulatory oversight.
It is important, however, not to treat “FDA GMP” as one identical framework for every FDA-regulated product category. Requirements differ according to the product.
For example, pharmaceutical drugs are subject to applicable drug CGMP regulations, while medical devices operate under FDA’s separate Quality Management System Regulation framework.
For pharmaceutical manufacturing specifically, therefore, the answer is clear: CGMP compliance is a legal requirement for drugs subject to FDA jurisdiction.
Trust Our Expert Answers?